spotlights latest AI-powered, software-defined MR smart systems at ECR 2022
Summary
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its SmartSpeed artificial intelligence (AI) powered MR acceleration software has received U.S. Food and Drug Administration (FDA) 510(k) clearance. Adding advanced AI data collection algorithms to Philips’ existing Compressed SENSE MR acceleration engine, Philips SmartSpeed delivers higher image resolution with 3 times faster scan times [1] and virtually no loss in image quality, representing a major step forward in diagnostic confidence and MR department productivity. With personalized treatment for complex diseases such as cancer increasing the need for high-confidence precision diagnoses, coupled with soaring caseloads due to aging populations and high levels of clinician burnout, radiology departments are under increasing pressure to improve performance, productivity, and profitability. Philips SmartSpeed, the latest addition to Philips’ expanding portfolio of AI-driven, smart, connected imaging and smart workflow solutions, helps achieve the Quadruple Aim of improving diagnostic outcomes, enhancing patient and staff experiences, and reducing healthcare costs overall. The unique deep learning technology of Philips SmartSpeed is applied at the source of the MR signal and seamlessly integrated with Philips leading Compressed SENSE speed engine to deliver higher resolution and high signal-to-noise ratio needed for detailed images, small lesion detection and enhanced diagnosis.